In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Idorsia Pharmaceuticals Ltd.

www.idorsia.com

Latest From Idorsia Pharmaceuticals Ltd.

Deal Watch: Molecular Templates Aligns With Vertex On Optimizing Stem Cell Candidates

Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.

Deals Business Strategies

Santhera Shores Up Finances With Chiesi Deal for Raxone

In a deal that could be worth CHF105m, the Swiss biotech has outlicensed Raxone to Chiesi for the rare eye disease LHON as it concentrates on the drug's filing for Duchenne muscular dystrophy.

Rare Diseases Companies

Finance Watch: Relay Raises $400m – And It's Only The Third-Largest Biopharma VC Round Of 2018

The company isn't relaying any details about its drug targets, but will use the mega-round to take its first candidates into the clinic. Also, RiverVest raises a $184.4m VC fund, Annexon closes a $75m Series C, Takeda lists its stock in the US, and Aptorum goes public.

Financing Business Strategies

Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies

BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Immune Disorders
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • R&D NewCo
  • Idorsia Ltd.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Idorsia Pharmaceuticals Ltd.
  • Senior Management
  • Jean-Paul Clozel, MD, CEO
    André C Muller, EVP, CFO
    Guy Braunstein, MD, PhD, Head, Global Clinical Dev.
    Martine Clozel, MD, EVP, CSO
    Simon Jose, EVP, Chief Commercial Officer
  • Contact Info
  • Idorsia Pharmaceuticals Ltd.
    Phone: 58 844 00 00
    Hegenheimermattweg 91
    Allschwil, 4123
    Switzerland
UsernamePublicRestriction

Register